PROM1 and glioblastoma: CAR T cells may also represent a promising GSC targeting strategy for GBM because a comparative evaluation of CD133 targeting immunotherapeutic strategies suggested a remarkable efficacy for CD133-specific CAR T cells without triggering adverse effects on hematopoietic stem cells [201].